U.S. drug distributor Cencora raised its annual profit forecast on Wednesday, driven by robust demand for costly specialty medicines and weight-loss drugs.

Shareholders might have noticed that Cencora, Inc. (NYSE:COR) filed its quarterly result this time last week. The early response was not positive, with shares down 3.1% to US$283 in the past week.

Shares of Cencora (COR) have been strong performers lately, with the stock up 11.2% over the past month. The stock hit a new 52-week high of $309.35 in the previous session. Cencora has gained 35. ...

Shares of Cencora Inc. COR shed 1.95% to $281.16 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.36% to 5,158.20 and Dow ...

CONSHOHOCKEN, Pa. (AP) — CONSHOHOCKEN, Pa. (AP) — Cencora, Inc. (COR) on Wednesday reported fiscal second-quarter profit of $717.9 million. On a per-share basis, the Conshohocken, Pennsylvania ...

Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a pharmaceutical sourcing and distribution company. With a market cap of approximately $54 billion, Cencora operates through the U.S ...